Hansa Biopharma AB (publ) (STO:HNSA)

Revenue by Segment

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Research and Development for Production of Pharmaceuticals	222.27M	171.32M	134.09M	154.53M	33.88M
Total	222.27M	171.32M	134.09M	154.53M	33.88M

Revenue by Geography

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Sweden	-	3.12M	-	4.68M	-
North America	14.09M	27.96M	27.42M	64.27M	15.71M
Europe (Ex Sweden)	202.28M	140.24M	106.68M	85.57M	18.17M
Rest of The World	5.90M	-	-	-	-
Total	222.27M	171.32M	134.09M	154.52M	33.88M

Data Source: S&P Global Market Intelligence Last updated: Jul 22, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 13, 2026

Data Sources Report a data error